This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Glibenclamide oral suspension

Updated 2 Feb 2023 | Sulfonylureas


Oral suspension of glibenclamide.

Drugs List

  • AMGLIDIA 600microgram/ml oral suspension with 1ml oral syringe
  • AMGLIDIA 600microgram/ml oral suspension with 5ml oral syringe
  • AMGLIDIA 6mg/ml oral suspension with 1ml oral syringe
  • AMGLIDIA 6mg/ml oral suspension with 5ml oral syringe
  • glibenclamide 600microgram/ml oral suspension sugar-free
  • glibenclamide 6mg/ml oral suspension sugar-free
  • Therapeutic Indications


    Treatment of neonatal diabetes mellitus in newborns, infants and children


    When using this agent, product literature, national guidelines and trust policies should be consulted.

    Maximum dose 1ml/kg/day. The 0.6mg/ml formulation should not be used for doses higher than 0.6mg/kg/day, due to the significant amount of sodium benzoate in the formulation.


    Inpatient treatment introduction
    Initially 0.2mg/kg daily in two divided doses before feeding.
    Increasing by increments of 0.2mg/kg daily. Maximum dose 1mg/kg.

    Specific dosing information regarding titration is not included. See product literature.

    Patients can be discharged once insulin is no longer required or when stable on either insulin alone or a combination of glibenclamide and insulin.

    Outpatient treatment introduction
    Increase by 0.2mg/kg daily in divided doses. Maximum dose 1mg/kg.

    Specific dosing information regarding titration is not included. See product literature.

    Additional Dosage Information

    Missed dose
    Check blood glucose immediately and take glibenclamide as soon as possible.


    Diabetic ketoacidosis
    Severe hepatic impairment
    Severe renal impairment

    Precautions and Warnings

    Restricted sodium intake
    G6PD deficiency
    Mild hepatic impairment
    Mild renal impairment

    Sodium content of formulation may be significant
    Contains sodium benzoate: may increase risk of jaundice in neonates
    Treatment to be initiated by specialist
    Administer 15 minutes before child's milk feeding
    Ensure correct strength and syringe are used for each administration
    Use designated delivery device only
    Monitor blood glucose before and during treatment
    Monitor dosage closely in presence of renal or hepatic impairment
    Monitoring of glycosylated haemoglobin is recommended
    Bioavailability differs with preparations;caution on changing formulations

    Cases of haemolytic anaemia have been reported in patients with G6PD enzyme deficiency, alternative treatment is recommended in these patients. Alternatively, a decision should be made taking into consideration the potential risks and benefits of treatment.

    Initial diarrhoea may occur upon increasing glibenclamide.

    If major vomiting occurs, a fast acting insulin should be used to treat patients. In minor vomiting, an antiemetic medicinal product should be given and glibenclamide treatment should continue.

    If blood glucose levels exceed 16.5 mmol/L monitor for the presence of ketonuria or ketonaemia. If ketone bodies are present, administer an insulin injection to restore metabolic situation. Patients with ketoacidosis should be placed on continuous intravenous insulin injection and intravenous infusion of physiologic saline.

    Pregnancy and Lactation


    Glibenclamide suspension is indicated only to treat newborns, infants and children.

    Use glibenclamide with caution during pregnancy.

    The manufacturer does not recommend using glibenclamide during pregnancy.

    At the time of writing there is limited published information regarding the use of glibenclamide during pregnancy. Available data does not indicate an increased risk of congenital malformations during the first trimester or fetotoxic effects in the second or third trimesters. Animal studies do not indicate a teratogenic potential. Glibenclamide crosses the placenta in small amounts, however this is variable between patients.

    Detailed guidance on the treatment of diabetes during pregnancy is available from the National Institute for Health and Clinical Excellence (NICE) at .


    Glibenclamide suspension is indicated only to treat newborns, infants and children.

    Use glibenclamide with caution during breastfeeding.

    The manufacturer states glibenclamide is compatible with breastfeeding, but advises blood sugar levels are monitored in breastfed infants.

    Available data indicates glibenclamide is not expressed in human breast milk, but the actual levels are unknown.

    Side Effects

    Abdominal pain
    Allergic skin reactions
    Anaphylactic reaction
    Bone marrow aplasia
    Bullous eruption
    Diarrhoea - transient
    Erythema multiforme
    Exfoliative dermatitis
    Increases in serum transaminases (transient)
    Skin photosensitivity
    Superficial tooth discolouration
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: August 2019

    Reference Sources

    Summary of Product Characteristics: Amglidia 0.6mg/ml oral suspension. Amring Sarl Ltd. Revised December 2018.

    Summary of Product Characteristics: Amglidia 6mg/ml oral suspension. Amring Sarl Ltd. Revised December 2018.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.